SEARCH

SEARCH BY CITATION

References

  • 1
    Ito K. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives. Int. J. Urol. 2009; 16: 458464.
  • 2
    Zelefsky MJ, Kollmeier M, Cox B et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012; 84: 125129.
  • 3
    Okamoto M, Ishikawa H, Ebara T et al. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate. Int. J. Radiat. Oncol. Biol. Phys. 2012; 82: e211217.
  • 4
    Ishikawa H, Tsuji H, Kamada T et al. Carbon-ion radiation therapy for prostate cancer. Int. J. Urol. 2012; 19: 296305.
  • 5
    Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920928.
  • 6
    Wakatsuki M, Tsuji H, Ishikawa H et al. Quality of life in men treated with carbon ion therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 10101015.
  • 7
    Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997) – Sobin – 2000 – Cancer – Wiley Online Library. Cancer 1997; 80: 18031804.
  • 8
    Tsuji H, Yanagi T, Ishikawa H et al. Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005; 63: 11531160.
  • 9
    Ishikawa H, Tsuji H, Kamada T et al. Carbon ion radiotherapy for prostate cancer: results of a prospective phase II study. Radiother. Oncol. 2006; 81: 5764.
  • 10
    Fowler JF. Total doses in fractionated radiotherapy implications of new radiobiological data. Int. J. Radiat. Biol. 1984; 46: 103120.
  • 11
    Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol. 1993; 11: 570579.
  • 12
    Auchter RM, Scholtens D, Adak S, Wagner S, Cella DF, Mehta MP. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 2001; 50: 11991206.
  • 13
    Cella D, Eton DT, Fairclough DL et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J. Clin. Epidemiol. 2002; 55: 285295.
  • 14
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457481.
  • 15
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys. 1995; 31: 13411346.
  • 16
    Pickles T, Kim-Sing C, Morris WJ, Tyldesley S, Paltiel C. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57: 1118.
  • 17
    Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int. J. Radiat. Oncol. 2001; 51: 614623.
  • 18
    Namiki S, Tochigi T, Kuwahara M et al. Health related quality of life in Japanese men after radical prostatectomy or radiation therapy for localized prostate cancer. Int. J. Urol. 2004; 11: 619627.
  • 19
    Litwin MS, Gore JL, Kwan L et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007; 11: 22392247.
  • 20
    Alemozaffar M, Regan MM, Cooperberg MR et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306: 12051214.
  • 21
    Fayers PM, Curran D, Machin D. Incomplete quality of life data in randomized trials: missing items. Stat. Med. 1998; 17: 679696.
  • 22
    Fairclough DL, Peterson HF, Chang V. Why are missing quality of life data a problem in clinical trials of cancer therapy? Stat. Med. 1998; 17: 667677.
  • 23
    Fumimoto H, Kobayashi K, Chang CH et al. Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese. Qual. Life Res. 2001; 10: 701709.
  • 24
    McKernan M, McMillan DC, Anderson JR, Angerson WJ, Stuart RC. The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer. Br. J. Cancer 2008; 98: 888893.
  • 25
    Qi Y, Schild SE, Mandrekar SJ et al. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J. Thorac. Oncol. 2009; 4: 10751082.
  • 26
    Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual. Life Outcomes 2009; 7: 102.
  • 27
    Kakehi Y, Kamoto T, Ogawa O et al. Development of Japanese version of the UCLA Prostate Cancer Index: a pilot validation study. Int. J. Clin. Oncol. 2002; 7: 306311.
  • 28
    Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899905.
  • 29
    Feigenberg SJ, Lee WR, Desilvio ML et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int. J. Radiat. Oncol. Biol. Phys. 2005; 62: 956964.
  • 30
    Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 15021512.